Reduced gene templates for supervised analysis of scale-limited CRISPR-Cas9 fitness screens.
CP: Molecular biology
CRISPR-Cas9 screen
cancer dependency
reference gene
scale-limited screen
supervised analysis
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
26 07 2022
26 07 2022
Historique:
received:
24
02
2022
revised:
26
05
2022
accepted:
07
07
2022
entrez:
29
7
2022
pubmed:
30
7
2022
medline:
3
8
2022
Statut:
ppublish
Résumé
Pooled genome-wide CRISPR-Cas9 screens are furthering our mechanistic understanding of human biology and have allowed us to identify new oncology therapeutic targets. Scale-limited CRISPR-Cas9 screens-typically employing guide RNA libraries targeting subsets of functionally related genes, biological pathways, or portions of the druggable genome-constitute an optimal setting for investigating narrow hypotheses and are easier to execute on complex models, such as organoids and in vivo models. Different supervised methods are used for computational analysis of genome-wide CRISPR-Cas9 screens; most are not well suited for scale-limited screens, as they require large sets of positive/negative control genes (gene templates) to be included among the screened ones. Here, we develop a computational framework identifying optimal subsets of known essential and nonessential genes (at different subsampling percentages) that can be used as templates for supervised analyses of scale-limited CRISPR-Cas9 screens, while having a reduced impact on the size of the employed library.
Identifiants
pubmed: 35905712
pii: S2211-1247(22)00954-8
doi: 10.1016/j.celrep.2022.111145
pii:
doi:
Substances chimiques
RNA, Guide
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111145Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests F.I. receives funds from Open Targets, a public-private initiative involving academia and industry. F.I. performs consultancy for the joint CRUK-AstraZeneca Functional Genomics Centre.